C. difficile 위험도


Severe infection (HAP, intraabdominal infection, gynecologic infection, bacteremia)Complicated UTIUncomplicated UTIUncomplicated gonorrhea12-18 g IV #4-6 (max 24 g/d)8-16 g IV #3-46-8 g IV #2-42 g IM 1 dose목동병원에서만 사용함

Safety and efficacy in pediatric patients <12y of age have not been established목동병원에서만 사용함

No dose adjustment

CrCl >40CrCl 20-40CrCl <20HDNo dose adjustment4 g IV q8h4 g IV q12h2 g IV q8h + 1 g IV after HD

CrCl >40CrCl 20-40CrCl <20HDNo dose adjustment3 g IV q8h3 g IV q12h2 g IV q8h + 1 g IV after HD

CrCl ≥20CrCl <20HDNo dose adjustment3 g IV q12h2 g IV q8h + 1 g IV after HD

General Information

  • Bacterial musculoskeletal infection

  • Female genital infection

  • Gonorrhea

  • Infection of skin and/or subcutaneous tissue

  • Infectious disease of abdomen

  • Lower respiratory tract infection

  • Postoperative infection; prophylaxis

  • Sepsis

  • Urinary tract infectious disease

Monitor renal function and serum electrolytes, liver function, CBC with differential.

  • Seizures

  • Rash

  • Haemolytic anaemia

  • Anaphylaxis

  • Thrombophlebitis

  • Tetracyclines - decreased antibacterial effectiveness

  • Vancomycin - increased risk of acute kidney injury

  • Warfarin- increased risk of bleeding

  • Vecuronium

  • Methotrexate

  • Seizure threshold-lowering agents

  • Cholera vaccine, live

Antimicrobial class: Ureidopenicillin

Pregnancy category: B

Average serum half life: 1 hour

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Attribution: Antimicrobial information adapted from Abia State (Nigerian Christian Hospital)

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.